SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001553350-22-000149
Filing Date
2022-02-14
Accepted
2022-02-11 17:47:23
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13G/A bria_13ga.htm SC 13G/A 43575
  Complete submission text file 0001553350-22-000149.txt   45294
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Subject) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: SC 13G/A | Act: 34 | File No.: 005-92289 | Film No.: 22623159
SIC: 2834 Pharmaceutical Preparations

Mailing Address 161A SHEDDEN ROAD ONE ARTILLARY COURT P.O. BOX 10085 GRAND KAYMAN E9 KY1-1001
Business Address 161A SHEDDEN ROAD ONE ARTILLARY COURT P.O. BOX 10085 GRAND KAYMAN E9 KY1-1001 646-688-5654
L1 Capital Global Opportunities Master Fund, Ltd. (Filed by) CIK: 0001702202 (see all company filings)

IRS No.: 981241877 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G/A